Mutations in this antigen are risk factors for carcinogenesis and are expressed in a variety of tumors, such as HER2-positive breast cancer (27), gastric cancer (28), metastatic colorectal cancer (29), and lung cancer (30). This evidence concerns the gene ERBB2 and lung carcinoma.